We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Agenus Inc | NASDAQ:AGEN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.15 | 9.49% | 13.27 | 13.26 | 13.50 | 13.67 | 11.76 | 11.80 | 933,882 | 00:43:53 |
LEXINGTON, Mass., Sept. 19, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's Leadership will present and host one-on-one meetings at two healthcare investment conferences in September. The details for the conferences are:
A live audio webcast will be available on the "Events & Presentations" section of the Company's investor website at www.agenusbio.com where a replay will also be available following the presentation.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content with multimedia:http://www.prnewswire.com/news-releases/agenus-to-present-at-two-healthcare-investor-conferences-in-september-300521712.html
SOURCE Agenus Inc.
Copyright 2017 PR Newswire
1 Year Agenus Chart |
1 Month Agenus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions